Fluorine??18 labeling of ML04–presently the most promising irreversible inhibitor candidate for visualization of EGFR in cancer

S Dissoki, D Laky, E Mishani

文献索引：Dissoki, Samar; Laky, Desideriu; Mishani, Eyal Journal of Labelled Compounds and Radiopharmaceuticals, 2006 , vol. 49, # 6 p. 533 - 543

全文：HTML全文

被引用次数: 26

摘要

Abstract Overexpression of the EGFR has been linked to cell malignancy, metastasis and poor prognosis thus making it a target for several FDA approved drugs such as Gefitinib and Erlotinib. Unfortunately, these drugs have yielded suboptimal clinical results. In order to evaluate and monitor EGFR-targeted treatment response at the molecular level, several PET biomarkers have been developed. One of the lead irreversible inhibitors (1) has been ...